--- title: "Plus Therapeutics (now Cerenome) gets Nasdaq deficiency notice over late Form" url: "https://aibio.space/news/plus-therapeutics-now-cerenome-gets-nasdaq-deficiency-notice-late-form/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-05-23" section: "Listings" tickers: "NASDAQ:CNSY" source: "https://www.sec.gov/Archives/edgar/data/1095981/000119312525125860/d947753d8k.htm" summary: "Nasdaq notified the company on May 21, 2025 that its late quarterly report breaks Listing Rule 5250(c)(1). It must submit an update to its compliance plan" --- By the aibio.space news desk. Sources - [CERENOME, INC. Form 8-K filed May 23, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1095981/000119312525125860/d947753d8k.htm) - [CERENOME, INC. exhibit d947753dex991.htm to the May 23, 2025 Form 8-K (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1095981/000119312525125860/d947753dex991.htm) - [CERENOME, INC. Form 10-K filed March 31, 2025: business overview and signatures (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1095981/000095017025047698/pstv-20241231.htm) [CNSY](https://aibio.space/companies/cerenome/) 2025-05-23 # Plus Therapeutics (now Cerenome) gets Nasdaq deficiency notice over late Form 10-Q Tickers [CNSY](https://aibio.space/companies/cerenome/) Nasdaq notified the company on May 21, 2025 that its late quarterly report breaks Listing Rule 5250(c)(1). It must submit an update to its compliance plan by July 21, 2025, and any exception could run until November 17, 2025. ## Key facts - **Company**: Cerenome, Inc. (NASDAQ: CNSY) - **News type**: Listings - **Primary source**: [CERENOME, INC. Form 8-K filed May 23, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1095981/000119312525125860/d947753d8k.htm) *The White House and its lawn. CC0, via rawpixel. The picture shows the field, not the companies named.* Plus Therapeutics, Inc. (now Cerenome, Inc.) said Nasdaq notified it on May 21, 2025 that it is not in compliance with Nasdaq Listing Rule 5250(c)(1), because it has not filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025 on time. The company disclosed the notice in a [Form 8-K filed May 23, 2025](https://www.sec.gov/Archives/edgar/data/1095981/000119312525125860/d947753d8k.htm) under Items 3.01 and 7.01. The filing and the press release use the Nasdaq symbol PSTV. ## What the notice requires The rule requires Nasdaq-listed companies to file all required periodic reports with the Securities and Exchange Commission on time. The notice gives the company until July 21, 2025 to submit an update to its plan to regain compliance. It also says any further exception to regain compliance with all delinquent filings is limited to up to 180 calendar days from the due date, or until November 17, 2025. The notice has no immediate effect on the listing of the company's securities. The press release repeats the July 21, 2025 date for the plan and says the company is working to file the quarterly report as promptly as practical. The press release, headlined as a notification of deficiency, calls the letter a delinquency notification and says the company expects to return to a normal filing cadence for the rest of 2025. The 8-K does not explain the cause of the delay. ## Cash and the going-concern warning The 2024 annual report says uncertainty about its ability to fund operations for at least the next 12 months raises substantial doubt about its ability to continue as a going concern. At December 31, 2024, the report says, the company had a working capital deficit of approximately $10.3 million and approximately $3.6 million of cash, cash equivalents and short-term investments. It used net cash of $10.6 million in operating activities in 2024. The same report states an accumulated stockholders' deficit of approximately $493.5 million at that date. It lists the risk of delisting from Nasdaq for failing the minimum stockholders' equity requirement, along with its ability to repay or refinance outstanding indebtedness. The company's market value of shares held by non-affiliates was $8.2 million on June 28, 2024, based on a $1.47 share price, according to the annual report. There were 16,999,626 shares outstanding as of March 21, 2025. ## The science and the business The 2024 annual report describes Plus Therapeutics as a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers. Its formulations encapsulate rhenium radionuclides in nanoliposomes and microspheres, which the company says are intended to achieve higher patient-absorbed radiation doses and longer retention of the isotope in the tumor. The filing describes these as intended effects, not as results from a controlled study. Its lead candidate, REYOBIQ (rhenium (186 Re) obisbemeda), is designed for central nervous system cancers including recurrent glioblastoma, leptomeningeal metastases and pediatric brain cancers. The press release names leptomeningeal metastases and recurrent glioblastoma as the lead programs and says the company is headquartered in Houston, Texas. ## What comes next The company's next step under the notice is the compliance plan, due July 21, 2025, and the late quarterly report itself. If the plan is accepted, the exception could run until November 17, 2025. The 8-K says the company continues to work diligently to complete the report, but it gives no date for filing. President and Chief Executive Officer Marc H. Hedrick, M.D. signed the 8-K. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story CNSY Cerenome, Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/plus-therapeutics-now-cerenome-gets-nasdaq-deficiency-notice-late-form/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Plus Therapeutics (now Cerenome) gets Nasdaq deficiency notice over late Form", 2025-05-23, https://aibio.space/news/plus-therapeutics-now-cerenome-gets-nasdaq-deficiency-notice-late-form/